| 000 | 02846nam a22004095i 4500 | ||
|---|---|---|---|
| 999 |
_c362884 _d362884 _x1 |
||
| 001 | 362884 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102121630.0 | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 210608s2021 sz | s |||| 0|eng d | ||
| 020 | _a9783030741730 | ||
| 024 | 7 |
_a10.1007/978-3-030-74173-0 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRM267 _b2021 EB |
|
| 100 | 1 |
_aPieper, Stefan _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9682405 |
|
| 245 | 1 | 0 |
_aFluoroquinolone-Associated Disability (FQAD) - Pathogenesis, Diagnostics, Therapy and Diagnostic Criteria _bSide-effects of Fluoroquinolones _cby Stefan Pieper. |
| 250 | _aFirst edition 2021 | ||
| 264 | 1 |
_aCham _bSpringer International Publishing _c2021 |
|
| 300 |
_a1 recurso en línea (X, 70 páginas) _b2 ilustraciones |
||
| 336 |
_2rdacontent _aTexto _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_aArchivo de texto _bPDF |
||
| 505 | 0 | _a1 Introduction to Fluoroquinolone-Associated Disability (FQAD) -- 2 FQAD and Oxidative Stress and Mitochondrial Toxicity -- 3 FQAD and Musculoskeletal Damage / Collagen Disorder -- 4 FQAD and Neurotoxicity / Peripheral Neuropathy (PN) / Autonomic Neuropathy / Small Fibre Neuropathy -- 5 FQAD and Neuropsychiatric Adverse Effects -- 6 Diagnostic criteria of the FQAD -- 7 Inside Story - Practical experience with FQAD Patients. | |
| 520 | _aIn this book, Stefan Pieper supports doctors and therapists in easily diagnosing FQAD and in better and more adequately dealing with FQAD patients. Fluoroquinolones, as one of the most common and effective groups of antibiotics, are known to have a distinct spectrum of side effects. These adverse effects are rare in percentage terms, but frequent in absolute numbers due to the enormous quantities of prescriptions. Because they are usually quite severe and wide-ranging, they tend to run like a syndrome and have been classified by the FDA as a separate condition, the FQAD, because of their frequency, severity and risk of disability. This book presents for the first time a comprehensive description and classification of the clinical picture and a proposal for a clinical diagnostic tool based on diagnostic criteria. | ||
| 988 | _aSpringer_Medicine_2021 | ||
| 650 | 7 |
_2embne _9138527 _aAntibióticos |
|
| 776 | 0 | 8 |
_iPrinted edition: _z9783030741723 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030741747 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-74173-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b02/2022 _dz _eb _zSI |
||